Novartis buys eczema drug in €95m deal

  Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and the German biotech company MorphoSys. The deal in which Novartis has agreed to pay €95 million, will transfer the exclusive global development and marketing rights for the atopic dermatitis (eczema) drug to the Swiss … Συνεχίστε να διαβάζετε Novartis buys eczema drug in €95m deal.